AREXVY
Generic: Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted
- Manufacturer
- GSK
- NDC
- 58160-848
- ICD-10 indication
- J12.1, J20.5
Affordability Check
How much will you actually pay for AREXVY?
In 30 seconds, see every legitimate way to afford AREXVY — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.
Copay & patient assistance
Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.
External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.
Compare pricing elsewhere
RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.
Cost Plus Drug Company
Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted.
Browse Cost Plus medications →
GoodRx
Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.
Lookup AREXVY →
NeedyMeds
Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.
Search for Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted →
RxAssist
PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.
Search PAPs →
We deep-link because transparency helps patients. None of these partners pay RxCopays.
Medicare Part D coverage
How AREXVY appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).
Covered by plans
81%
4,480 of 5,509 plans
Most common tier
Tier 1
On 54% of covering formularies
Prior authorization required
21%
of covering formularies
| Tier | Formularies on this tier | Share |
|---|---|---|
| Tier 1 (preferred generic) | 178 | 54% |
| Tier 2 (generic) | 11 | 3% |
| Tier 3 (preferred brand) | 100 | 30% |
| Tier 4 (non-preferred brand) | 4 | 1% |
| Tier 6 | 36 | 11% |
Step therapy: 0% of formularies
Quantity limits: 41% of formularies
Coverage breadth: 329 of 65 formularies
How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).
Prior authorization & coverage
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
— Medicare Part D | — | — | — |
Related drugs
Arnuity Ellipta
Also from GSK · fluticasone furoate
Trelegy Ellipta
Also from GSK · fluticasone furoate, umeclidinium bromide and vilanterol trifenatate
BENLYSTA
Also from GSK · belimumab
SUMATRIPTAN
Also from GSK · Sumatriptan Succinate
Ojjaara
Also from GSK · Momelotinib
Umeclidinium and Vilanterol Ellipta
Also from GSK · umeclidinium bromide and vilanterol trifenatate
ZEJULA
Also from GSK · niraparib
Mupirocin
Also from GSK · Mupirocin
Jesduvroq
Also from GSK · daprodustat
How this page is sourced
- Drug identity verified against openFDA NDC Directory.
- Label text (when shown) originates from NLM DailyMed.
- Copay and assistance URLs verified periodically; if you hit a broken link, tell us.